Skip to main content
CRVO
NASDAQ Life Sciences

CervoMed Advances Lead Drug Candidate Neflamapimod to Phase 3 with Optimized Dosing for Dementia with Lewy Bodies

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.96
Mkt Cap
$37.196M
52W Low
$1.92
52W High
$16.94
52W Position info
106% above low
Off High info
77% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

CRVO has more than doubled off its 52-week low of $1.92.

Summary

CervoMed Inc. announced the successful completion of a Phase 1 study for neflamapimod and the selection of a 50mg TID dose for its planned Phase 3 trial in dementia with Lewy bodies, addressing prior manufacturing variability.


Key Events · Product Development and Regulatory · CRVO

  • Phase 1 Study Successfully Completed

    CervoMed Inc. announced the successful completion of a Phase 1 healthy volunteer study evaluating the pharmacokinetics of a new, stable crystal form of its lead drug candidate, neflamapimod.

  • Phase 3 Dosing Regimen Selected

    The company has selected 50mg three times per day (TID) as the dose and dosing regimen for its planned pivotal Phase 3 trial in patients with dementia with Lewy bodies (DLB).

  • Manufacturing Challenges Addressed

    The new dosing strategy and stable crystal form of neflamapimod aim to mitigate prior manufacturing challenges related to cross-batch variability and ensure plasma drug concentrations consistent with therapeutically active batches from previous trials.

  • Pivotal Phase 3 Trial Planned

    CervoMed plans to initiate the global Phase 3 trial in DLB patients in the second half of 2026, contingent on securing sufficient funding.


Analysis · CRVO · Life Sciences

CervoMed Inc. has achieved a significant milestone by successfully completing a Phase 1 study for its lead drug candidate, neflamapimod, and subsequently selecting the optimal dose for its pivotal Phase 3 trial in dementia with Lewy bodies (DLB). This development is crucial for a clinical-stage biotechnology company, as it de-risks the drug's progression by addressing prior manufacturing challenges related to polymorphs and bioavailability. The company's decision to increase the dose to 50mg TID is a strategic move to ensure plasma drug concentrations align with those that demonstrated significant clinical activity in previous trials, providing a clearer path forward for the planned Phase 3 trial in the second half of 2026, subject to funding.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRVO was trading at $3.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.2M. The 52-week trading range was $1.92 to $16.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRVO - Latest Insights

CRVO
Nov 16, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.48 info
Change: -$0.170 (-10%) info
Market Cap: $22.542M info
CRVO
Nov 06, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.48 info
Change: +$0.060 (+4%) info
Market Cap: $22.542M info
CRVO
Oct 29, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.48 info
Change: -$0.270 (-15%) info
Market Cap: $22.542M info
CRVO
Oct 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.48 info
Change: -$1.54 (-51%) info
Market Cap: $22.542M info
CRVO
Sep 28, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.48 info
Change: -$1.15 (-44%) info
Market Cap: $22.542M info